Online adaptive radiotherapy for nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a new type of radiation therapy that adjusts in real-time to treat nasopharyngeal cancer. It is for people who have not received prior radiation and have no distant spread of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with nasopharyngeal cancer (a type of throat cancer) that is non-keratinizing.
- You are between 18 and 70 years old.
- Cancer has not spread to other parts of your body.
- You are able to lie still for at least 30 minutes without feeling claustrophobic.
- You are willing to sign a consent form and follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether lowering the radiation dose to a smaller area around the tumor is safe and effective for people with newly diagnosed nasopharyngeal cancer that has not spread. It may reduce side effects while still curing the cancer.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
This Phase 3 trial tests giving chemotherapy first, then either radiation alone or chemotherapy together with radiation. It aims to improve treatment control for people with newly diagnosed, advanced nasopharyngeal cancer.
This trial tests a combination of chemotherapy (three drugs: docetaxel, cisplatin, and fluorouracil) plus an immunotherapy drug (a PD-1 inhibitor, which helps your immune system fight cancer) given before the standard radiation treatment for nasopharyngeal cancer. The goal is to see if this upfront treatment can improve outcomes in patients whose cancer has not spread to distant parts of the body.
This trial compares two treatment options for people with nasopharyngeal cancer that did not respond well to initial chemotherapy. One option is to switch to a different chemotherapy regimen, the other is to go straight to radiation therapy. The study aims to see which approach is more effective in this situation.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.